We’re dedicated to providing quality immune cell products. Your research and innovations depend on our cells working as described. We’ve always stood behind our products, but wanted to make our dedication to quality even more transparent in our new guarantee: If your order does not match the specifications on the Certificate of Analysis, we will…
We may not have to wait much longer for the first FDA-approved CAR-T cell therapy. The Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) recently recommended Novartis’ CTL019 CAR-T cell therapy for FDA approval by unanimous decision, a major step forward for the groundbreaking biologic. CTL019, indicated for pediatric and young adult r/r B…
When you buy immune cell products, you want a supplier that is committed to providing quality cells using a sustainable business model. If you find a cell type or donor you need, you should be able to order the same product again and again until your research needs are met. We believe in sustainable business…
New research on PD-1 and PD-L1 inhibitors is raising questions on the positive and negative effects of popular cancer treatments, calling for further studies. PD-L1 Inhibits Chronic Pain in Mice Ru-Rong Ji (Duke University) and Yu-Qiu Zhang (Fudan University) have shown that PD-L1 can lessen acute and chronic pain when injected into mice. The team…